Professor | Shu Shaokun | Asia Growth Partners

	Upload Avatar (500 x 500)
Name	Shu Shaokun
Contact Information	shaokun_shu@bjmu.edu.cn
Language ability	Chinese, English
Province	Beijing

Upload Avatar (500 x 500)

Name

Shu Shaokun

Contact Information

shaokun_shu@bjmu.edu.cn

Language ability

Chinese, English

Province

Beijing

University/Lab Affiliation and Title	Peking University
Faculty	Basic Medical Sciences
Academic Background & Achievements	1999-2003 Bachelor in Bioengineering, Beijing Institute of Technology 2005-2010 PhD in Molecular Oncology, University of South Florida
Work Experience	2003.8 – 2005.8: Chinese Academy of Sciences, Research Assistant 2011.1 – 2011.8: University of South Florida, Postdoctoral Fellow 2011.8 – 2019.8: Dana-Farber Cancer Institute, Harvard Medical School, Postdoctoral Fellow/Lecturer 2019.9 – present: Peking University Cancer Hospital & Institute, Researcher
Awards	2017: Jon Shevell Young Scientist Scholarship, Keyston Epigenetics symposium, Seattle 2016: Jon Shevell Young Scientist Scholarship, Cold Spring Harbor Annual Meeting, New York 2015: AACR Breast Cancer training award, AACR Breast Cancer Annual Meeting, Seattle 2010: Travel award and oral presentation, American Association for Cancer Research, Mini-symposium

University/Lab Affiliation and Title

Peking University

Faculty

Basic Medical Sciences

Academic Background & Achievements

1999-2003 Bachelor in Bioengineering, Beijing Institute of Technology
2005-2010 PhD in Molecular Oncology, University of South Florida

Work Experience

2003.8 – 2005.8: Chinese Academy of Sciences, Research Assistant
2011.1 – 2011.8: University of South Florida, Postdoctoral Fellow
2011.8 – 2019.8: Dana-Farber Cancer Institute, Harvard Medical School, Postdoctoral Fellow/Lecturer
2019.9 – present: Peking University Cancer Hospital & Institute, Researcher

Awards

2017: Jon Shevell Young Scientist Scholarship, Keyston Epigenetics symposium, Seattle
2016: Jon Shevell Young Scientist Scholarship, Cold Spring Harbor Annual Meeting, New York
2015: AACR Breast Cancer training award, AACR Breast Cancer Annual Meeting, Seattle
2010: Travel award and oral presentation, American Association for Cancer Research, Mini-symposium

Areas of Focus	Oncological Epigenetics Targeted Therapy Tumor Microenvironment Combination Drug Therapy High-throughput Gene Editing Screening (CRISPR Screen)
Publications	Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer, Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K, 2020 Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer, Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K, 2020 Response and resistance to BET bromodomain inhibitors in triple negative breast cancer, Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K, 2016 BET Bromodomain Proteins as Cancer Therapeutic Targets, Shu S, Polyak K, 2016 Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments, Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K, 2019 TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer, Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K, 2018 Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes, Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K, 2016

Areas of Focus

Oncological Epigenetics
Targeted Therapy
Tumor Microenvironment
Combination Drug Therapy
High-throughput Gene Editing Screening (CRISPR Screen)

Publications

Synthetic Lethal and Resistance Interactions with BET Bromodomain Inhibitors in Triple-Negative Breast Cancer, Shu S, Wu HJ, Ge JY, Zeid R, Harris IS, Jovanović B, Murphy K, Wang B, Wucherpfennig KW, Qi J, Liu XS, Long H, Brown M, Carroll JS, Brugge JS, Bradner J, Michor F, Polyak K, 2020
Acquired resistance to combined BET and CDK4/6 inhibition in triple-negative breast cancer, Ge JY, Shu S, Kwon M, Jovanović B, Murphy K, Gulvady A, Fassl A, Trinh A, Kuang Y, Heavey GA, Luoma A, Paweletz C, Thorner AR, Wucherpfennig KW, Qi J, Brown M, Sicinski P, McDonald TO, Pellman D, Michor F, Polyak K, 2020
Response and resistance to BET bromodomain inhibitors in triple negative breast cancer, Shu S, Lin CY, He HH, Witwicki RM, Tabassum DP, Roberts JM, Janiszewska M, Huh SJ, Liang Y, Ryan J, Doherty E, Mohammed H, Guo H, Stover DG, Ekram MB, Peluffo G, Brown J, D'Santos C, Krop IE, Dillon D, McKeown M, Ott C, Qi J, Ni M, Rao PK, Duarte M, Wu SY, Chiang CM, Anders L, Young RA, Winer EP, Letai A, Barry WT, Carroll JS, Long HW, Brown M, Liu XS, Meyer CA, Bradner JE, Polyak K, 2016
BET Bromodomain Proteins as Cancer Therapeutic Targets, Shu S, Polyak K, 2016
Subclonal cooperation drives metastasis by modulating local and systemic immune microenvironments, Janiszewska M, Tabassum DP, Castaño Z, Cristea S, Yamamoto KN, Kingston NL, Murphy KC, Shu S, Harper NW, Del Alcazar CG, Alečković M, Ekram MB, Cohen O, Kwak M, Qin Y, Laszewski T, Luoma A, Marusyk A, Wucherpfennig KW, Wagle N, Fan R, Michor F, McAllister SS, Polyak K, 2019
TRPS1 Is a Lineage-Specific Transcriptional Dependency in Breast Cancer, Witwicki RM, Ekram MB, Qiu X, Janiszewska M, Shu S, Kwon M, Trinh A, Frias E, Ramadan N, Hoffman G, Yu K, Xie Y, McAllister G, McDonald R, Golji J, Schlabach M, deWeck A, Keen N, Chan HM, Ruddy D, Rejtar T, Sovath S, Silver S, Sellers WR, Jagani Z, Hogarty MD, Roberts C, Brown M, Stegmaier K, Long H, Shivdasani RA, Pellman D, Polyak K, 2018
Spatial Proximity to Fibroblasts Impacts Molecular Features and Therapeutic Sensitivity of Breast Cancer Cells Influencing Clinical Outcomes, Marusyk A, Tabassum DP, Janiszewska M, Place AE, Trinh A, Rozhok AI, Pyne S, Guerriero JL, Shu S, Ekram M, Ishkin A, Cahill DP, Nikolsky Y, Chan TA, Rimawi MF, Hilsenbeck S, Schiff R, Osborne KC, Letai A, Polyak K, 2016

Epigenetics Therapy Tumor Microenvironment Drug High-Throughput Gene Editing Crispr Screening

Jiadong Wang - Peking University

Qiang Zhang - Zhejiang University

Chunyi Jiang - Nanjing Medical University

View All

Personal Information

Academic Information

Research

Contact us

No account yet?

Personal Information

Academic Information

Research

Contact us